1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: YUNZHI-BC, NCT00647075
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: simcere002, simcere0802, NCT00813332
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML22780, 2009-014279-37, NCT01094184
|
|
4.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
|
|
5.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25288, NCT01301729
|
|
6.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P0334, NCT01501487
|
|
7.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Approved-not yet active Age: 20 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2011-91, NCT01571518
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 20 to 70 Sponsor: Other Protocol IDs: 4-2011-0068, NCT01660542
|
|
9.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV08, NCT01665417
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000455008, MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
|
|
11.
|
Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 17 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: PH-CP010, NCT00518869
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 59 Sponsor: Other Protocol IDs: M09TNM, 2009-015238-31, NCT01057069
|
|
13.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BREC-AGC, NCT01206218
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FLOT4, NCT01216644
|
|
15.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-08, NCT01348126
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 9thShanghai, 10DZ1951300, NCT01434394
|
|
17.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EGC-0254/87/2011, UML-EGC-2011, NCT01523015
|
|
18.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: TPF for resectable OSCC, 2007BAI18B03, NCT01542931
|
|
19.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: GU004-11, NCT01603420
|
|
20.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: Other Protocol IDs: TENBC, NCT01648608
|
|
21.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 20111220, NCT01689558
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000068827, IBCSG-22-00, EU-20119, EUDRACT-2005-005666-36, NCT00022516
|
|
23.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SAKK 16/00, SWS-SAKK-16/00, EU-20138, NCT00030771
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DUMC03, DUKE UNIVERSITY MEDICAL CENTER, CLINICAL STUDY PROTOCOL, NCT00090610
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000393548, DFCI-04006, AVENTIS-DFCI-04006, PARADIGM TRIAL, NCT00095875
|